SUPPLY CHAIN
“ THE BENEFITS OF COLLABORATION ACROSS PRIVATE BUSINESS AND PUBLIC GOVERNMENTS REALLY ACCELERATED VACCINE DEVELOPMENT ”
ERIC LEMAY HEAD OF GLOBAL EXTERNAL MANUFACTURING , SERVIER
freedom and flexibility to operate , as opposed to a publicly-traded pharmaceutical company that may have stakeholder pressures .
“ At the forefront of our mission are our patients ,” said Lemay . “ Everything we do is based on our patients , it ' s not shareholder value or anything like that . Yet this doesn ' t make us immune to the supply chain challenges that every other pharmaceutical company has faced . One of the things that we ' re most proud of is that , even through the pandemic and with all the challenges we ' ve had , we have not stocked out . Our people have put in hard work to think creatively and do things differently to ensure a patient never goes without product .
“ We ’ re working with our contract manufacturing sites to order things way further in advance . Where we typically would hold maybe three or six months of safety stock of some of those critical materials , we may have up to a year ' s worth instead , just to limit any susceptibility within the global supply chain .
Current challenges in the pharmaceutical supply chain Having navigated the COVID-19 pandemic , what ’ s next for Servier and the supply chain ?
healthcare-digital . com 101